Compare FUL & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FUL | CLDX |
|---|---|---|
| Founded | 1887 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.6B |
| IPO Year | 2007 | 1995 |
| Metric | FUL | CLDX |
|---|---|---|
| Price | $60.17 | $44.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $68.40 | $46.60 |
| AVG Volume (30 Days) | 570.1K | ★ 927.2K |
| Earning Date | 03-25-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.57% | N/A |
| EPS Growth | ★ 19.57 | N/A |
| EPS | ★ 1.61 | N/A |
| Revenue | ★ $2,897,000,000.00 | $12,743,000.00 |
| Revenue This Year | $4.96 | $111.39 |
| Revenue Next Year | $4.00 | $235.85 |
| P/E Ratio | $38.53 | ★ N/A |
| Revenue Growth | N/A | ★ 87.78 |
| 52 Week Low | $48.71 | $20.37 |
| 52 Week High | $68.63 | $44.60 |
| Indicator | FUL | CLDX |
|---|---|---|
| Relative Strength Index (RSI) | 58.26 | 78.38 |
| Support Level | $58.21 | $28.51 |
| Resistance Level | $62.04 | N/A |
| Average True Range (ATR) | 1.63 | 1.56 |
| MACD | 0.72 | 0.70 |
| Stochastic Oscillator | 75.11 | 96.49 |
H.B. Fuller Co manufactures and sells adhesives, sealants, and other chemical-based products. The company organizes itself into three segments: Hygiene, Health and Consumable Adhesives, Engineering Adhesives, and Construction Adhesives. It generates the maximum revenue from hygiene, health, and consumable adhesives. This segment produces and supplies a full range of specialty industrial adhesives such as thermoplastic, thermoset, reactive, water-based, and solvent-based products for applications in various markets, including packaging, converting, nonwoven, and hygiene (disposable diapers, feminine care, and medical garments) and health and beauty. The company generates around half of its revenue in the United States.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.